Trial Profile
A Phase 2, Multicenter, Randomized Open-Label Study to Determine the Efficacy of Lenalidomide (Revlimid) Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Chlorambucil; Cytarabine; Fludarabine; Fludarabine; Gemcitabine; Rituximab
- Indications Mantle-cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms SPRINT
- Sponsors Celgene Corporation
- 13 Aug 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.
- 23 Jan 2019 This trial was completed in Greece (End date; 2018-10-09), according to European Clinical Trials Database record.